298 related articles for article (PubMed ID: 29484520)
1. Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.
Passey C; Suryawanshi S; Sanghavi K; Gupta M
AAPS J; 2018 Feb; 20(2):35. PubMed ID: 29484520
[TBL] [Abstract][Full Text] [Related]
2. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
[TBL] [Abstract][Full Text] [Related]
3. The Immunogenicity of Biologic Therapies.
Garcês S; Demengeot J
Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
Kimball AB; Kerbusch T; van Aarle F; Kulkarni P; Li Q; Blauvelt A; Papp KA; Reich K; Montgomery D
Br J Dermatol; 2020 Jan; 182(1):180-189. PubMed ID: 30916381
[TBL] [Abstract][Full Text] [Related]
5. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
[TBL] [Abstract][Full Text] [Related]
6. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
[TBL] [Abstract][Full Text] [Related]
7. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.
Wang YM; Wang J; Hon YY; Zhou L; Fang L; Ahn HY
AAPS J; 2016 Mar; 18(2):395-403. PubMed ID: 26721560
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.
Agrawal S; Statkevich P; Bajaj G; Feng Y; Saeger S; Desai DD; Park JS; Waxman IM; Roy A; Gupta M
J Clin Pharmacol; 2017 Mar; 57(3):394-400. PubMed ID: 27557786
[TBL] [Abstract][Full Text] [Related]
11. Drug monitoring of biologics in inflammatory bowel disease.
Eser A; Primas C; Reinisch W
Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
[TBL] [Abstract][Full Text] [Related]
12. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor Types.
Valentine JL; Dengler A; Zhao A; Truong T; McAfee S; Hassanein M; Irvin SC; Chen J; Meng X; Yan H; Torri A; Sumner G; Andisik MD; Paccaly A; Partridge MA
J Clin Pharmacol; 2024 Jan; 64(1):125-136. PubMed ID: 37656820
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
15. Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?
Hassanein M; Partridge MA; Shao W; Torri A
Bioanalysis; 2020 Sep; 12(18):1325-1336. PubMed ID: 32946271
[TBL] [Abstract][Full Text] [Related]
16. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.
Sloan JH; Conway RG; Pottanat TG; Troutt JS; Higgs RE; Konrad RJ; Qian YW
Bioanalysis; 2016 Oct; 8(20):2157-68. PubMed ID: 27593891
[TBL] [Abstract][Full Text] [Related]
17. Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.
Goodman J; Cowen S; Devanarayan V; Egging D; Emrich T; Golob M; Kramer D; McNally J; Munday J; Nelson R; Pedras-Vasconcelos JA; Piironen T; Sickert D; Skibeli V; Fjording MS; Timmerman P
Bioanalysis; 2018 Feb; 10(4):197-204. PubMed ID: 29345496
[TBL] [Abstract][Full Text] [Related]
18. Scientific and regulatory considerations on the immunogenicity of biologics.
Shankar G; Shores E; Wagner C; Mire-Sluis A
Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies.
Vaisman-Mentesh A; Gutierrez-Gonzalez M; DeKosky BJ; Wine Y
Front Immunol; 2020; 11():1951. PubMed ID: 33013848
[TBL] [Abstract][Full Text] [Related]
20. Isotyping and Semi-Quantitation of Monkey Anti-Drug Antibodies by Immunocapture Liquid Chromatography-Mass Spectrometry.
Huang X; Xu X; Partridge MA; Chen J; Koehler-Stec E; Sumner G; Qiu H; Torri A; Li N
AAPS J; 2021 Jan; 23(1):16. PubMed ID: 33404777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
